GFM
RYTM icon

GF Fund Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

GF Fund Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$161K Sell
1,448
-50
-3% -$4.52K ﹤0.01% 292
2026
Q1 		$130K Buy
1,498
+188
+14% +$18.3K ﹤0.01% 316
2025
Q4 		$140K Sell
1,310
-119
-8% -$12.6K ﹤0.01% 320
2025
Q3 		$144K Sell
1,429
-144
-9% -$13.4K ﹤0.01% 313
2025
Q2 		$99.4K Hold
1,573
– – ﹤0.01% 367
2025
Q1 		$83.3K Buy
1,573
+283
+22% +$15.7K ﹤0.01% 378
2024
Q4 		$72.2K Buy
+1,290
New +$71.3K ﹤0.01% 358

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GF Fund Management's RYTM Position: Q2 2026 in Review

GF Fund Management reduced its Rhythm Pharmaceuticals (RYTM) stake by 3.3% in Q2 2026, selling an estimated $4.52K and leaving 1,448 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #292.

GF Fund Management first reported a position in RYTM in Q4 2024 and has held it in 7 quarters since. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • GF Fund Management held 1,448 shares of Rhythm Pharmaceuticals worth $161K as of Q2 2026.
  • GF Fund Management sold 50 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.52K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #292 holding.
  • GF Fund Management first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.